|
|
Post by tinkusr8215 on Nov 1, 2018 22:14:33 GMT -5
All this positive, highly optimistic news regarding the future of MNKD is music to my ears. Though, we hear this every time they have a webcast, it still gives me hope. After all on March 1st of 2017 4 out of every 5 shares I owned were taken from me in the 5:1 reverse split. I went from over 200k shares to +40k shares in one day, that hurt. But, it's nice to know that Mike C and the rest of the MNKD team is really working hard to make this company successful. My struggle is that while this is happening, and I'm buying and selling MNKD to get my bottom dollar less, I might miss the big move. Or if I conceive a big move and then buy into thinking I'm going to miss it, I might get stuck again when the price doesn't make the big move and comes back down again. Or do I keep buying the stock while its cheap and wait it out....like I have been doing anyway... I think many of us may be in the same boat? yes in the same boat. and o/s increased from 96 million to 159 mill and it should stop here ( except the warrants and employee stock purchases - 30 million shares..warrants atleast get 2+ $ for MNKD , but employee purchases only net a buck ) . so almost 100% increase which halved the size of our pie.
|
|
|
|
Post by tinkusr8215 on Oct 29, 2018 18:52:10 GMT -5
finally.
|
|
|
|
Post by tinkusr8215 on Oct 26, 2018 17:08:21 GMT -5
All patents must explain how the invention works and provide evidence of it working. You can read the patents by Googling: Justia patents 9610351 and 9233159 That tells me about the patent. I am asking about the "Blockbuster" part of the patent. |
|
|
|
Post by tinkusr8215 on Oct 25, 2018 19:13:34 GMT -5
once United gives all the details of the deal the day before , Mannkind can discuss more on the details the next day. Additional deal would be nice bonus.
|
|
|
|
Post by tinkusr8215 on Oct 21, 2018 10:33:08 GMT -5
It may partly depend on the questions the analysts ask them. I just went to their ST site and all they’re talking about is us:-) On UTHR stocktwits , I see majority posts are from MNKD investors as their posts are multi tagged $MNKD $UTHR and other posts are from bots. May be I am blocked by UTHR folks as well. Not sure.
|
|
|
|
Post by tinkusr8215 on Oct 18, 2018 20:46:30 GMT -5
I heard V is for Verify from a user here.
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 21:00:04 GMT -5
You are missing my point. Just having a list is not good enough for potential partners to throw away money. If you notice for PAH , pre IND phase completion and discussing results with FDA and trial design could have triggered the talks with potential suitors. I dont see that pre IND phase past for the other two or any in the list ( which may be outdated?). unless some company has money to gamble.
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 14:21:22 GMT -5
Don’t forget that MC made a point to mention a possible molecule partnership with Novartis in his last cc as well. Would be huge if they did a second or third molecule partnership outside of UTHR with a big pharmaceutical like Novartis. Am not saying they will but no reason for MC to mention if not thinking of it or perhaps in very early discussions. On August 31, Mylan NV (NYSE: MYL) acknowledged that it paid $463 million for Novartis’ cystic fibrosis products. Novartis sold the worldwide rights to commercialize its cystic fibrosis products TOBI Podhaler (tobramycin inhalation powder) and TOBI (tobramycin solution for inhalation). Mylan expects to pay $240 million this year, with the rest coming later. |
|
|
|
Post by tinkusr8215 on Oct 16, 2018 13:13:51 GMT -5
Don’t forget that MC made a point to mention a possible molecule partnership with Novartis in his last cc as well. Would be huge if they did a second or third molecule partnership outside of UTHR with a big pharmaceutical like Novartis. Am not saying they will but no reason for MC to mention if not thinking of it or perhaps in very early discussions. for PAH, some basic trials were done and discussed with FDA which might have gathered interest from partners since initial results seemed positive. Any internal trials in this second or third molecule?
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 12:42:53 GMT -5
Now that the uncertainty is taken off , slow and steady increase based on hope and there's always a chance that United can proceed on the second compound as well ( $30 mil upfront if so ).
United can also buy in if required to raise $. ( Hoping we don't have to and can run with out any dilution)
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 11:04:35 GMT -5
Is this the answer to the original question?
As previously announced, the effectiveness of the agreement was conditioned upon expiration or termination of the required waiting period under the Hart-Scott-Rodino Antitrust Improvements Act. The requisite waiting period expired on October 15, 2018, and the agreement became effective the same day.
|
|
|
|
Post by tinkusr8215 on Oct 16, 2018 7:49:57 GMT -5
Not liking seeing it as medium term launch. Is medium term in 12 months or 12 to 24 months or 24+ months?
Does Mannkind / United have a time line as to when the trials SHOULD be done in the contract, so United doesnt drag the trials along?
|
|
|
|
Post by tinkusr8215 on Oct 14, 2018 0:04:03 GMT -5
All of the above were allficted at a sensitive time for a biotect start up / don’t take Adam for granted he’s not there for no reason / he has the talent to reek havoc on small bios arent v deviating from our original so called "corruption"? |
|
|
|
Post by tinkusr8215 on Oct 13, 2018 23:04:43 GMT -5
Martin shkerli, Margaret Hamburg, Adam fuerstien, possible SANOFI-AVENTIS, bogus complete response letter .. Can you point out what was bogus in the CRL? SNY deal was both ways - It took both companies to sign the deal. If the deal wasnt so good or possible deception , why would MNKD sign it? Adam is drop of water in the stock market ocean. He may write articles on companies and cause them to sell off but real companies with solid revenue never go down on such articles. Investing in biotech is very volatile and built on speculation and based on trial results.
Margaret Hamburg - Is MNKD only the company that got the CRL?
On the other hand - How do you think a company with revenue reported for the last 3 years could sustain a 4 billion market cap? Why didnt you complain of the over valuation?
Do you have analysts expectation or any one's projection for that matter of Afrezza revenue expected to be per year for that valuation? I do vaguely remember that Mankind was estimating Afrezza sales to be 150 mil the first yr of launch.
|
|
|
|
Post by tinkusr8215 on Oct 13, 2018 21:59:56 GMT -5
I have said for years , this is more a 60 mins story. An investigational story of money, corruption, and science , along with hopefully a happy 😃 ENDING. Except MS who wrote that letter to FDA.. everything else is a by product of how the company was run by its officers. Can you elaborate your corruption theory - I would love to hear.
|
|
